Scarica l'app Stockscreener
50.26
1.68%
-0.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics (CYTK) Projected to Post Earnings on Tuesday - MarketBeat
Allspring Global Investments Holdings LLC Has $4.11 Million Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Van ECK Associates Corp - MarketBeat
Cytokinetics, Incorporated (CYTK): One of the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - MSN
Insider Sell: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Fady Ibraham Malik Sells 2,000 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Peregrine Capital Management LLC - MarketBeat
Cytokinetics EVP sells $91,960 in stock By Investing.com - Investing.com South Africa
Stifel maintains Buy on Cytokinetics stock, target at $80 By Investing.com - Investing.com Canada
Cytokinetics EVP sells $91,960 in stock - Investing.com
Cytokinetics (NASDAQ:CYTK) Stock Price Up 7.6%Time to Buy? - MarketBeat
Cytokinetics stock touches 52-week low at $41.69 amid market challenges - MSN
Cytokinetics (NASDAQ:CYTK) Upgraded by Morgan Stanley to "Overweight" Rating - MarketBeat
Cytokinetics jumps amid renewed takeover speculation - MSN
CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study - MSN
Cytokinetics (NASDAQ:CYTK) Reaches New 1-Year LowHere's What Happened - MarketBeat
Harvey Capital Management Inc. Acquires Shares of 22,105 Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics upgraded by Morgan Stanley on upside potential - MSN
Morgan Stanley Upgrades Cytokinetics (CYTK) - MSN
Cytokinetics to Announce Fourth Quarter Results on February 27, 2025 - EIN News
Morgan Stanley Upgrades Cytokinetics to Overweight From Equalweight, Trims Price Target to $67 From $70 - Marketscreener.com
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 - MSN
Morgan Stanley lifts Cytokinetics stock rating, cuts target to $67 By Investing.com - Investing.com UK
Cytokinetics adds pharma veteran Landry to board ahead of drug launch - Investing.com Nigeria
Cytokinetics' (CYTK) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Citigroup - MarketBeat
Cytokinetics Names Robert E. Landry to Board of Directors - GlobeNewswire
Cytokinetics adds pharma veteran Landry to board ahead of drug launch By Investing.com - Investing.com South Africa
Cytokinetics Appoints Robert E. Landry to Board - TipRanks
Cytokinetics Names Robert E. Landry To Board Of Directors -February 11, 2025 at 07:53 am EST - Marketscreener.com
Cytokinetics Appoints Robert E. Landry to Board of Directors to Enhance Financial and Operational Expertise as Company Prepares for Commercialization - Nasdaq
abrdn plc Acquires 102,457 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Sets New 12-Month LowShould You Sell? - MarketBeat
JMP Securities maintains Cytokinetics stock with $78 target - MSN
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):